Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05583227 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
A Phase 3 study of Eosinophilic Esophagitis, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 368
- Enrollment target
- 20
- Study locations
NCT05583227 is a Phase 3 study of Eosinophilic Esophagitis that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 368 participants, below the 856-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT05583227, a Phase 3 study of Eosinophilic Esophagitis, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 368 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Tezepelumab
Study Locations (20)
Florida
- Research Site - Inverness
- Research Site - Jacksonville
- Research Site - Saint Augustine
Pennsylvania
- Research Site - Philadelphia
- Research Site - Smithfield
Arizona
- Research Site - Phoenix
Arkansas
- Research Site - Little Rock
California
- Research Site - Los Angeles
Colorado
- Research Site - Aurora
Illinois
- Research Site - Normal
Iowa
- Research Site - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2022-11-10 |
| Est. Completion | 2027-03-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05583227
The ClinicalTrials.gov registry entry for NCT05583227 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 368 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 856-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (57% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05583227 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Florida, Pennsylvania, Arizona.
Frequently Asked Questions
What is clinical trial NCT05583227 about?
NCT05583227 is a clinical study titled "Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis". A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).
What is the current status of trial NCT05583227?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 368 participants. The study started on 2022-11-10. Estimated completion is 2027-03-23.
What conditions does trial NCT05583227 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT05583227?
The interventions under investigation include: Placebo (OTHER), Tezepelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05583227?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05583227 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
RECRUITING · Phase 3
-
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
COMPLETED · Phase 3
-
Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)
COMPLETED · Phase 3
-
Characteristics and Inflammatory Markers in Children with Eosinophilic Esophagitis (EoE)
RECRUITING
-
Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.